CK Life Sciences (00775) has declined more than 4%, bringing its cumulative loss for the month to nearly 15%. As of the latest update, the stock fell 4% to HK$0.72, with a turnover of HK$5.93 million. The company released its annual results, reporting revenue of HK$5.41 billion, down 2% year-on-year. The loss attributable to shareholders widened to HK$187 million, an increase of 47.61% compared to the previous year. According to the announcement, the increased loss of HK$60.2 million in the 2025 fiscal year compared to 2024 reflects a rise in research and development expenses of HK$66.5 million, along with several non-recurring and one-time items.